DFDA

Leukotriene Receptor Antagonists (LTRAs)

Treatment for Allergic Rhinitis

Typical Dosage: 10mg once daily (e.g., Montelukast)

Effectiveness
65%
Safety Score
55%
Clinical Trials
200
Participants
30K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
10mg once daily (e.g., Montelukast)
Time to Effect
1-2 weeks
Treatment Duration
Seasonal or daily as needed
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2000(Treat 2000 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$25
Side Effect Mgmt:$10
Total Annual:$215
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$430
Cost per Remission
$3,071.43
Comparison vs Intranasal Corticosteroids
Cost Difference
$0/year
Same cost
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Prescription Access Economics
Leukotriene Receptor Antagonists (LTRAs) Outcomes

for Allergic Rhinitis

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+50%
Remission Rate
+7%
Common Side Effects
Headache
+12%
Gastrointestinal upset
+7%
Neuropsychiatric events
+0.5%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov